Shots:
- The US FDA has approved Emblaveo (IV) + metronidazole for pts (≥18 yrs) with few or no therapy options for cIAI caused by susceptible gram -ve bacteria, incl. E. coli, K. pneumoniae, K. oxytoca, ECC, C. freundii complex, & S. marcescens; commercially available in Q3’25
- Approval was based on prior aztreonam’s efficacy & safety data for cIAI, plus P-III (REVISIT) trial, assessing Emblaveo ± metronidazole vs meropenem ± colistin in 422 pts with cIAI or nosocomial pneumonia (HAP/VAP); data published in The Lancet
- Emblaveo combines aztreonam (monobactam) & avibactam (β-lactamase inhibitor) that protects aztreonam from serine β-lactamase (SBL) hydrolysis, while restoring its activity against MBL- & SBL-producing bacteria
Ref: Abbvie | Image: Abbvie
Related News:- Abbvie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Oncology and Immunology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
